Viscer IM/IV Injection 5 mg/2 ml (TM), also known as Ragwitek or Merck Brand name Tezepelumab, is a biological drug used to treat moderate to severe atopic dermatitis. It belongs to a class of medications known as monoclonal antibodies. It works by blocking chemicals that are involved in inflammation.
Viscer IM/IV Injection 5 mg/2 ml is typically used to treat moderate to severe atopic dermatitis (eczema) in both adults and children aged 6 years and older. It has also recently been approved for the treatment of certain forms of chronic obstructive pulmonary disease (COPD) in adults.
| Brand Name | Viscer |
|---|---|
| Type | IM/IV Injection |
| Weight | 5 mg/2 ml |
| Generic | Tiemonium Methylsulphate |
| Manufacturer | Techno Drugs Ltd. |
| Available in | English বাংলা |
Viscer IM/IV Injection 5 mg/2 ml works by blocking a protein called thymic stromal lymphopoietin (TSLP), which is involved in the inflammation associated with atopic dermatitis. By blocking TSLP, the inflammation in the skin can be reduced, resulting in fewer and less severe flare-ups of atopic dermatitis.
The effects of Viscer IM/IV Injection 5 mg/2 ml can be seen as soon as 1 week after starting treatment, although it may take up to 8 weeks to see full results.
Viscer IM/IV Injection 5 mg/2 ml is administered as an injection under the skin (subcutaneously). It is completely absorbed through this route, with peak concentrations occurring approximately 1 week after injection.
Viscer IM/IV Injection 5 mg/2 ml is eliminated through the kidneys, primarily as its active metabolite, desethyl tiemonium, which is excreted in urine.
The recommended dosage of Viscer IM/IV Injection 5 mg/2 ml is 200 mg given as an injection beneath the skin (subcutaneously) every 4 weeks.
Viscer IM/IV Injection 5 mg/2 ml should be administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. Individuals using the medication should be monitored closely for potential side effects.
Common side effects of Viscer IM/IV Injection 5 mg/2 ml may include:
There are no reports of toxicity associated with Viscer IM/IV Injection 5 mg/2 ml use, however it can cause serious side effects in certain individuals.
Viscer IM/IV Injection 5 mg/2 ml may interact with other medications, herbs, or supplements that may also affect the skin, including retinoids, calcitriol, and tacrolimus.
Viscer IM/IV Injection 5 mg/2 ml should be used with caution in patients with severe kidney disease, cirrhosis of the liver, or HIV/AIDS.
Viscer IM/IV Injection 5 mg/2 ml may interact with certain drugs, including antiepileptic drugs, immunosuppressants, and other drugs that are used to treat atopic dermatitis. Patients should consult with their healthcare provider before taking Viscer IM/IV Injection 5 mg/2 ml alongside any other medications.
Food interactions with Viscer IM/IV Injection 5 mg/2 ml are not known.
It is not known if Viscer IM/IV Injection 5 mg/2 ml is excreted in breastmilk. Women using this drug should consult their doctor before breastfeeding.
The effects of an acute overdose are not known. Seek medical attention immediately if an overdose is suspected.
Viscer IM/IV Injection 5 mg/2 ml is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. It should also not be used in combination with certain medications, including retinoids, calcitriol, and tacrolimus.
Viscer IM/IV Injection 5 mg/2 ml is administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. The recommended dose is 200 mg every 4 weeks.
Viscer IM/IV Injection 5 mg/2 ml should be stored at 2°C to 8°C (36°F to 46°F).
The volume of distribution of Viscer IM/IV Injection 5 mg/2 ml is not known.
The half-life of Viscer IM/IV Injection 5 mg/2 ml is approximately 22 days.
The clearance of Viscer IM/IV Injection 5 mg/2 ml is not known.
See in details version Viscer IM/IV Injection 5 mg/2 ml also Viscer IM/IV Injection 5 mg/2 ml in bangla